Meet the ApiJect Business Development Team
Our Approach
At ApiJect, our Business Development team partners with you to provide a turnkey combination product development through commercial manufacturing solution using our single-use blow-fill-seal injection platform. We work with you to identify the appropriate injector device design, ensure feasibility and identify a manufacturing solution that best fits your injectable or vaccine needs.
|
Bo Kowalczyk, Chief Commercial Officer |
|
 Bo Kowalczyk has an extensive career spanning more than 25 years in the biopharmaceutical industry encompassing the entire spectrum of pharmaceutical drug development, and currently serves as the Chief Commercial Officer. Bo brings a wealth of expertise to ApiJect and is spearheading the company’s efforts to develop and commercialize its injectable drug delivery technology platform. Prior to joining ApiJect, Bo was the Vice President of Sales, North America, at Syngene International’s Chemical Development and Manufacturing division. He skillfully aligned operational excellence with targeted prospecting, identifying optimal business opportunities and enhancing client satisfaction. As Global VP at Eurofins Biologics Bioanalytical Services, Bo’s leadership seamlessly integrated services crucial for clinical trial logistics and sample testing support by merging Bioanalytical Services with Eurofins Central Lab Services. He served as Vice President, Business Development and Marketing at AIT Bioscience, where he achieved remarkable sales and profitability growth over five years. Notably, he established a network of third-party preclinical toxicology service providers, strategically positioning AIT Bioscience for early access to promising therapeutic candidates transitioning into clinical trials and future commercial launch. Bo Kowalczyk’s client-centric, solution-oriented approach to business development with a robust network in the drug development industry to connect sponsors with service providers have solidified his industry reputation. |
|
|
PJ Kim, Vice President, Business Development |
|
|
PJ Kim’s 19+ years in regulated pharmaceuticals, healthcare, and clinical trials includes responsibilities in quality, sales, program management, key account management, and corporate strategy. At ApiJect, Mr. Kim is responsible for developing strategic plans for new and existing key accounts in drug delivery design, development, and manufacturing utilizing ApiJect’s technology. Previously, Mr. Kim served as an Executive Director in Syngene International’s NA CDMO business, developing new integrated drug development programs. Earlier posts included Pharmaceutics International’s Head of Commercial and Corporate Development, and Account Manager with Johnson Matthey, identifying API portfolio business opportunities and negotiating contracts. At Advanced Bioscience Laboratories, he was directly responsible for new growth, capturing and developing key large pharma and R&D programs. As Head of Quality and Regulatory at Cleveland Clinic’s Taussig Cancer Institute, he managed a team of monitors and auditors ensuring compliance the NCI regulations on IND studies. His career began at Ben Venue Laboratories starting as a bench chemist, moving to quality assurance, and eventually landing in account management focusing on servicing BVL’s sterile injectable clients. Mr. Kim earned his MBA from Baldwin-Wallace College and a Bachelor’s in Biology with a Chemistry minor at Case Western Reserve. |
|
| Morgan Amsler, Director, Business Development | |
|
Morgan Amsler has 11+ years of experience leading mid-market life science and medical device business growth initiatives including sales, corporate strategy, and new business development. At ApiJect, Mr. Amsler will lead business development efforts in the U.S. as well as manage licensing agreements for the ApiJect Platform of technologies to companies developing injectable vaccines, generics, new chemical entities, and biosimilar therapeutics. Mr. Amsler was Vice President of Sales & Business Development and an Executive Board Member for Arcmed, a subsidiary company of Halma plc. He managed organic and acquired growth initiatives and strategy through the integration and transformation of two leading life science manufacturers. Previously, Mr. Amsler served as Director of Business Development where he managed business development, valuation, negotiations, and acquisition for ophthalmic devices at Microsurgical Technologies. Previous positions include Director of Innovation for Halma Healthcare Sector, New Product Development Manager for Acutome, and a Founding Member of the Futures Leaders Program at Halma. Mr. Amsler earned his MBA from Columbia Business School and a Bachelor’s Degree with a focus on Biomedical Engineering from Vanderbilt University. |
|
